Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS South Australia Inc

Registered Charity 3104


Mailing address:

PO Box 322,
Modbury North,
South Australia 5092

1300 128 339

Office Hours:
Monday - Friday,
10am - 4pm

ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.


ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
DOCX Application Form (Word, 198 KB)
Why become a member?

A New Test For Chronic Fatigue Syndrome

Sunday 15 November 2020


From Australian news outlet Mirage:


Dr Alain Moreau
Dr Alain Moreau

A new test for chronic fatique syndrome

November 13, 2020
Mirage.News 2020. We acknowledge the traditional owners of country throughout Australia.

Myalgic encephalomyelitis (ME), better known as chronic fatigue syndrome, is a complex chronic disease affecting some 600,000 Canadians and up to 2.5 million Americans. It’s also poorly understood: until now there has been no validated blood biomarker or test to diagnose the disease.

Researchers at CHU Sainte-Justine and Université de Montréal led by Dr. Alain Moreau have developed an innovative diagnostic test that makes it possible for the first time to test patients who cannot participate in clinical studies due to the severity of their condition.

Led by Dr. Alain Moreau, a professor in the faculties of dentistry and medicine at UdeM, the researchers detail their innovation in a study published today in’s Scientific Reports.

The development of this test represents the first molecular diagnostic tool for ME and one that has been long awaited by many clinicians and patients, say Moreau and his team. It also opens up the possibility of classifying patients into subgroups to better understand the molecular mechanisms involved in their symptoms and to better select patients who could benefit from therapeutic approaches by repositioning existing drugs.


Full article...



blog comments powered by Disqus
Previous Previous Page